Thursday, 21 Sep 2017

You are here

Treat-to-Target in Spondyloarthropathies

Today's session, Treat to target in axSpA: reality or utopia?, was opened with a presentation by Dr. Jurgen Braun (Herne, Germany), who masterfully reintroduced us to the treat-to-target concept in spondyloarhtropathies.

Similar to how diabetes control and outcomes improved with introduction of treat to target concept in endocrinology, rheumatologists are looking to adopt similar strategies for more effective management of rheumatic disease outcomes.

In his presentation today Dr. Braun raised two important questions:

  1. what is the target in treatment of rheumatic diseases? and

  2. is T2T applicable in SpA?

While more easily defined in rheumatoid arthritis, remission is a more complicated target in SpA with axial involvement. The majority of published studies conclude that overall mortality and morbidity in SpA is linked to disease activity. Longitudinal relationship as observed between disease activity and radiographic damage over time:

Existent treatment guidelines are helpful in achieving treatment. When used in T2T approach, ASDAS showed to be effective outcome measure in axSpA comparable to DAS in RA.

 

Dr. Braun concluded that T2T can be effectively used in SpA and patients would benefit if rheumatologists follow this concept.

Add new comment

More Like This

CDC: 40% of U.S Adults Claim to Have Arthritis

The CDC has reported its 2013 and 2014 prevalence statistics for arthritis and other chronic medical conditions affecting U.S. adults aged ≥18 years. Data is drawn from the ongoing Behavioral Risk Factor Surveillance System (BRFSS), a state-based, telephone survey of noninstitutionalized adults. Data herein is self-reported arthritis (OA, RA, Gout, FM) and is quantified by state and metropolitan areas.

15 September 2017 The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report discusses metabolic syndrome in lupus, bisphosphonate holidays, vasculitis and vascular inflammation, vaccination, and the repeated wonders of Vitamin D.

Why Rheumatologists Should Do Better Vaccinating this Flu Season

It is well known that influenza infection is more common in patients with rheumatologic diseases. Blumentals et al. showed that patients with rheumatoid arthritis are at increased risk for influenza regardless of DMARD/biologic use and may have a 2.75-fold increased incidence of related complications (https://buff.ly/2gYNTSz).

8 September 2017: The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report includes trends in MTX use and outcomes, fibromyalgia as an inflammatory disorder, drugs that stop psoriasis pruritus, drugs that don't cause TB, cardiovascular risk, and what Rheums think of ACR/EULAR criteria.

1 September 2017: The RheumNow Week in Review

This week's report includes new data on IL-1 inhibition and protection from CV events and lung cancer, baricitinib given a reprieve, and features on infections: HBV, shingles and mortality of septic arthritis.